Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
Harold Bays, Angela Fitch, Sandra Christensen +2 more2022Obesity PillarsJournal Article
Endocrine (ADH/ACTH/MSH)
Abstract
This "Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association Clinical Practice Statement 2022" is one of a series of OMA CPSs designed to assist clinicians in the care of patients with pre-obesity/obesity.
Part of CIRS Nexus · Curated by Lauren Lowenstein, The Biotoxin Lady
Related Papers
- Pro-resolving and anti-arthritic properties of the MC1 selective agonist PL8177Frontiers in Immunology · 2022 · 1 shared tag
- Probing the VIPR2 Microduplication Linkage to Schizophrenia in Animal and Cellular ModelsFrontiers in Neuroscience · 2021 · 1 shared tag
- CGRP sensory neurons promote tissue healing via neutrophils and macrophagesNature · 2024 · 1 shared tag
- Invited review: Mechanisms of hypophagia during diseaseJournal of Dairy Science · 2021 · 1 shared tag
- Considering traditional Chinese medicine as adjunct therapy in the management of chronic constipation by regulating intestinal floraBioScience Trends · 2024 · 1 shared tag
- Lipid-Induced Insulin Resistance Mechanisms: The Link to Inflammation and Type 2 Diabetes.2021 · 1 shared tag